Descriptions

The autoinhibited protein was predicted that may have potential autoinhibitory elements via cis-regPred.

Autoinhibitory domains (AIDs)

Target domain

Relief mechanism

Assay

cis-regPred

Accessory elements

No accessory elements

Autoinhibited structure

Activated structure

17 structures for Q04048

Entry ID Method Resolution Chain Position Source
5GM6 EM 350 A v 569-734 PDB
5GMK EM 340 A v 569-734 PDB
5LJ3 EM 380 A T 1-859 PDB
5LJ5 EM 380 A T 1-859 PDB
5LQW EM 580 A P 1-859 PDB
5MPS EM 385 A T 1-859 PDB
5MQ0 EM 417 A T 1-859 PDB
5WSG EM 400 A v 569-734 PDB
5Y88 EM 370 A H 1-859 PDB
5YLZ EM 360 A H 1-859 PDB
6BK8 EM 330 A U 1-859 PDB
6EXN EM 370 A T 1-859 PDB
6J6G EM 320 A v 1-859 PDB
6J6H EM 360 A v 1-859 PDB
6J6N EM 386 A v 1-859 PDB
6J6Q EM 370 A v 1-859 PDB
AF-Q04048-F1 Predicted AlphaFoldDB

22 variants for Q04048

Variant ID(s) Position Change Description Diseaes Association Provenance
s04-1298586 55 K>Q No SGRP
s04-1298680 86 E>G No SGRP
s04-1298821 133 A>D No SGRP
s04-1298950 176 T>I No SGRP
s04-1299024 201 S>G No SGRP
s04-1299165 248 E>K No SGRP
s04-1299250 276 A>V No SGRP
s04-1299498 359 G>R No SGRP
s04-1299525 368 F>L No SGRP
s04-1299650 409 E>D No SGRP
s04-1299799 459 R>T No SGRP
s04-1299811 463 I>T No SGRP
s04-1300138 572 M>T No SGRP
s04-1300218 599 Y>H No SGRP
s04-1300380 653 K>E No SGRP
s04-1300465 681 S>N No SGRP
s04-1300513 697 S>N No SGRP
s04-1300632 737 P>S No SGRP
s04-1300743 774 P>S No SGRP
s04-1300795 791 H>L No SGRP
s04-1300879 819 S>N No SGRP
s04-1300948 842 T>N No SGRP

No associated diseases with Q04048

8 regional properties for Q04048

Type Name Position InterPro Accession
repeat HAT (Half-A-TPR) repeat 13 - 49 IPR003107-1
repeat HAT (Half-A-TPR) repeat 52 - 84 IPR003107-2
repeat HAT (Half-A-TPR) repeat 88 - 121 IPR003107-3
repeat HAT (Half-A-TPR) repeat 516 - 554 IPR003107-4
repeat HAT (Half-A-TPR) repeat 597 - 633 IPR003107-5
repeat HAT (Half-A-TPR) repeat 639 - 675 IPR003107-6
repeat HAT (Half-A-TPR) repeat 720 - 754 IPR003107-7
repeat HAT (Half-A-TPR) repeat 756 - 790 IPR003107-8

Functions

Description
EC Number
Subcellular Localization
  • Nucleus
PANTHER Family
PANTHER Subfamily
PANTHER Protein Class
PANTHER Pathway Category No pathway information available

8 GO annotations of cellular component

Name Definition
cytosol The part of the cytoplasm that does not contain organelles but which does contain other particulate matter, such as protein complexes.
nucleus A membrane-bounded organelle of eukaryotic cells in which chromosomes are housed and replicated. In most cells, the nucleus contains all of the cell's chromosomes except the organellar chromosomes, and is the site of RNA synthesis and processing. In some species, or in specialized cell types, RNA metabolism or DNA replication may be absent.
post-mRNA release spliceosomal complex A spliceosomal complex that is formed following the release of the spliced product from the post-spliceosomal complex and contains the excised intron and three snRNPs, including U5.
Prp19 complex A protein complex consisting of Prp19 and associated proteins that is involved in the transition from the precatalytic spliceosome to the activated form that catalyzes step 1 of splicing, and which remains associated with the spliceosome through the second catalytic step. It is widely conserved, found in both yeast and mammals, though the exact composition varies. In S. cerevisiae, it contains Prp19p, Ntc20p, Snt309p, Isy1p, Syf2p, Cwc2p, Prp46p, Clf1p, Cef1p, and Syf1p.
U2-type catalytic step 1 spliceosome A spliceosomal complex that is formed by the displacement of the U1 and U4 snRNPs from the precatalytic spliceosome; the U2, U5 and U6 snRNPs remain associated with the mRNA. This complex, sometimes called the activated spliceosome, is the catalytically active form of the spliceosome, and includes many proteins in addition to those found in the U2, and U5 and U6 snRNPs.
U2-type catalytic step 2 spliceosome A spliceosomal complex that contains the U2, U5 and U6 snRNPs bound to a splicing intermediate in which the first catalytic cleavage of the 5' splice site has occurred. The precise subunit composition differs significantly from that of the catalytic step 1, or activated, spliceosome, and includes many proteins in addition to those found in the U2, U5 and U6 snRNPs.
U2-type post-mRNA release spliceosomal complex A spliceosomal complex that is formed following the release of the spliced product from the post-spliceosomal complex and contains the excised intron and the U2, U5 and U6 snRNPs.
U2-type prespliceosome A spliceosomal complex that is formed by association of the 5' splice site with the U1 snRNP, while the branch point sequence is recognized by the U2 snRNP. The prespliceosome includes many proteins in addition to those found in the U1 and U2 snRNPs. Commitment to a given pair of 5' and 3' splice sites occurs at the time of prespliceosome formation.

No GO annotations of molecular function

Name Definition
No GO annotations for molecular function

2 GO annotations of biological process

Name Definition
generation of catalytic spliceosome for first transesterification step Formation of a catalytic spliceosome complex ready to perform the first splicing reaction. This occurs by an ATP-dependent conformational change of the pre-catalytic spliceosome.
mRNA splicing, via spliceosome The joining together of exons from one or more primary transcripts of messenger RNA (mRNA) and the excision of intron sequences, via a spliceosomal mechanism, so that mRNA consisting only of the joined exons is produced.

3 homologous proteins in AiPD

UniProt AC Gene Name Protein Name Species Evidence Code
Q9HCS7 XAB2 Pre-mRNA-splicing factor SYF1 Homo sapiens (Human) PR
Q9DCD2 Xab2 Pre-mRNA-splicing factor SYF1 Mus musculus (Mouse) PR
Q99PK0 Xab2 Pre-mRNA-splicing factor SYF1 Rattus norvegicus (Rat) PR
10 20 30 40 50 60
MSAYIAMKGV ITNVDENIRN DEDVAFEYEI QKTPQNILTW KRYIEYWKEE GRTDKQIRWL
70 80 90 100 110 120
YERFCSQFVT DTSIWEDYIR WESTKEVVET SRIFWLFQRC LKSCVRDCDR ICLSYLELAI
130 140 150 160 170 180
EQYDLAMIRH ALASSLMKME REMHRKVWDP VIKFVEEKVL PLTQLDSTQE DEEESTDEAE
190 200 210 220 230 240
LINVLLVKGF TKGGFISEEI SENGSRGDIW SSHILERYLK VAPQQKRNES LATLALTRDN
250 260 270 280 290 300
ITIKSVYEKY LPQDENSGKY LPSSELPFEL NFNYLASLEK LGLDNQYEEF MRQMNGIYPD
310 320 330 340 350 360
KWLFLILSLA KYYISRGRLD SCGDLLKKSL QQTLRYSDFD RIYNFYLLFE QECSQFILGK
370 380 390 400 410 420
LKENDSKFFN QKDWTEKLQA HMATFESLIN LYDIYLNDVA LRQDSNLVET WMKRVSLQKS
430 440 450 460 470 480
AAEKCNVYSE AILKIDPRKV GTPGSFGRLW CSYGDLYWRS NAISTARELW TQSLKVPYPY
490 500 510 520 530 540
IEDLEEIYLN WADRELDKEG VERAFSILED ALHVPTNPEI LLEKYKNGHR KIPAQTVLFN
550 560 570 580 590 600
SLRIWSKYID YLEAYCPKDA NSSDKIFNKT KMAYNTVIDL RLITPAMAEN FALFLQNHYE
610 620 630 640 650 660
VMESFQVYEK TIPLFPPEIQ YELWIEYLEV ATSHQLSSLS PEHIRFLFEK ALKNLCSNGI
670 680 690 700 710 720
DCKTIFIAYS VFEERISGLI SKSIEILRRG AVIGTVSVST HLESRLQLWR MCISKAESTL
730 740 750 760 770 780
GPSVTRELYQ ECIQILPNSK AVEFVIKFSD FESSIGETIR AREILAYGAK LLPPSRNTEL
790 800 810 820 830 840
WDSFEIFELK HGDKETYKDM LKMKKVLESN MLIDSASVSH EEGNINFVAA ATSHAPNSHT
850
LTQSTSSYSI NPDEIELDI